Focal Treatment or Observation of Prostate Cancer: Pretreatment Accuracy of Transrectal Ultrasound Biopsy and T2-weighted MRI

Urology

Volumn 75, Issue 2, 2010, Pages 472-477

  Nogueira, Lucas ^a   Wang, Liang ^a   Fine, Samson W ^a   Pinochet, Rodrigo ^a   Kurta, Jordan M ^a   Katz, Darren ^a   Savage, Caroline J ^a   Cronin, Angel M ^a   Hricak, Hedvig ^a   Scardino, Peter T ^a   Akin, Oguz ^a   Coleman, Jonathan A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ADULT; ARTICLE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RECTUM BIOPSY; TRANSRECTAL ULTRASONOGRAPHY;

BIOPSY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RECTUM; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; ULTRASONOGRAPHY;

EID: 75349114312     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.04.061     Document Type: Article

References (27)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Cooperberg M.R., Lubeck D.P., Meng M.V., et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 22 (2004) 2141-2149
3. Carroll P.R. Early stage prostate cancer-do we have a problem with over-detection, overtreatment or both?. J Urol 173 (2005) 1061-1062
4. Cooperberg M.R., Moul J.W., and Carroll P.R. The changing face of prostate cancer. J Clin Oncol 23 (2005) 8146-8151
5. Eggener S.E., Scardino P.T., Carroll P.R., et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol 178 (2007) 2260-2267
6. Klotz L.H., and Nam R.K. Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a "number needed to treat" analysis. Can J Urol 13 suppl 1 (2006) 48-55
7. Shukla-Dave A., Hricak H., Kattan M.W., et al. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int 99 (2007) 786-793
8. Yossepowitch O., Sircar K., Scardino P.T., et al. Bladder neck involvement in pathological stage pT4 radical prostatectomy specimens is not an independent prognostic factor. J Urol 168 (2002) 2011-2015
9. Goto Y., Ohori M., Arakawa A., et al. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 156 (1996) 1059-1063
10. Ohori M., Wheeler T.M., Dunn J.K., et al. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 152 (1994) 1714-1720
11. Epstein J.I., Walsh P.C., and Carter H.B. Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol 166 (2001) 1688-1691
12. Stattin P., Holmberg E., Bratt O., et al. Surveillance and deferred treatment for localized prostate cancer. Population based study in the national prostate cancer register of Sweden. J Urol 180 (2008) 2423-2429 Discussion:2429-2430
13. Hardie C., Parker C., Norman A., et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int 95 (2005) 956-960
14. Miller D.C., Gruber S.B., Hollenbeck B.K., et al. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 98 (2006) 1134-1141
15. Meiers I., Waters D.J., and Bostwick D.G. Preoperative prediction of multifocal prostate cancer and application of focal therapy: review 2007. Urology 70 (2007) 3-8
16. Ohori M., Eastham J.A., Koh H., et al. Is focal therapy reasonable in patients with early stage prostate cancer (CaP)-an analysis of radical prostatectomy (RP) specimens. J Urol 175 (2006) 507 Abstract:1574
17. Scales Jr. C.D., Presti Jr. J.C., Kane C.J., et al. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy-results from the SEARCH database. J Urol 178 (2007) 1249-1252
18. Bostwick D.G., Myers R.P., and Oesterling J.E. Staging of prostate cancer. Semin Surg Oncol 10 (1994) 60-72
19. Pinthus J.H., Witkos M., Fleshner N.E., et al. Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol 176 (2006) 979-984 Discussion:984
20. Chun F.K., Briganti A., Graefen M., et al. Development and external validation of an extended repeat biopsy nomogram. J Urol 177 (2007) 510-515
21. Crawford E.D., Wilson S.S., Torkko K.C., et al. Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy. BJU Int 96 (2005) 999-1004
22. Merrick G.S., Taubenslag W., Andreini H., et al. The morbidity of transperineal template-guided prostate mapping biopsy. BJU Int 101 (2008) 1524-1529
23. Moran B.J., Braccioforte M.H., and Conterato D.J. Re-biopsy of the prostate using a stereotactic transperineal technique. J Urol 176 (2006) 1376-1381 Discussion:1381
24. Hricak H. MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer. Br J Radiol 78 Spec. No 2 (2005) S103-S111
25. Kozlowski P., Chang S.D., Jones E.C., et al. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis-correlation with biopsy and histopathology. J Magn Reson Imaging 24 (2006) 108-113
26. Kirkham A.P., Emberton M., and Allen C. How good is MRI at detecting and characterising cancer within the prostate?. Eur Urol 50 (2006) 1163-1174 Discussion:1175
27. Wang L., Hricak H., Kattan M.W., et al. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 238 (2006) 597-603